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Germline Heterozygous Variants in SEC23B
Are Associated with Cowden Syndrome
and Enriched in Apparently Sporadic Thyroid Cancer
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Zhigang Liu,1,2 Wei Wei,1,2,7 Jessica L. Mester,1,2 Ruth A. Keri,8,9 Bin Zhang,1,2
and Charis Eng1,2,10,11,12,*
Cancer-predisposing genes associated with inherited cancer syndromes help explain mechanisms of sporadic carcinogenesis and often
inform normal development. Cowden syndrome (CS) is an autosomal-dominant disorder characterized by high lifetime risks of epithe-
lial cancers, such that ~50% of affected individuals are wild-type for known cancer-predisposing genes. Using whole-exome and Sanger
sequencing of a multi-generation CS family affected by thyroid and other cancers, we identified a pathogenic missense heterozygous
SEC23B variant (c.1781T>G [p.Val594Gly]) that segregates with the phenotype. We also found germline heterozygous SEC23B variants
in 3/96 (3%) unrelated mutation-negative CS probands with thyroid cancer and in The Cancer Genome Atlas (TCGA), representing
apparently sporadic cancers. We note that the TCGA thyroid cancer dataset is enriched with unique germline deleterious SEC23B var-
iants associated with a significantly younger age of onset. SEC23B encodes Sec23 homolog B (S. cerevisiae), a component of coat protein
complex II (COPII), which transports proteins from the endoplasmic reticulum (ER) to the Golgi apparatus. Interestingly, germline ho-
mozygous or compound-heterozygous SEC23Bmutations cause an unrelated disorder, congenital dyserythropoietic anemia type II, and
SEC23B-deficientmice suffer from secretory organ degeneration due to ER-stress-associated apoptosis. By characterizing the p.Val594Gly
variant in a normal thyroid cell line, we show that it is a functional alteration that results in ER-stress-mediated cell-colony formation
and survival, growth, and invasion, which reflect aspects of a cancer phenotype. Our findings suggest a different role for SEC23B,
whereby germline heterozygous variants associate with cancer predisposition potentially mediated by ER stress ‘‘addiction.’’Introduction
Cowden syndrome (CS [MIM: 158350]) is an under-
diagnosed difficult-to-recognize autosomal-dominant dis-
order characterized by multiple hamartomas and an
increased predisposition to breast, thyroid, endometrial,
and other cancers. Other, non-neoplastic phenotypes
include macrocephaly and mucocutaneous findings.1,2
The tumor-suppressor gene phosphatase and tensin ho-
molog (PTEN [MIM: 601728]) was identified as the first
susceptibility gene for CS.3,4 Earlier studies identified
germline PTEN mutations in 85% of CS individuals1,5
meeting the strict International Cowden Consortium
(ICC) operational diagnostic criteria, which select for
familial cases and exaggerated phenotypes accrued from
tertiary medical centers.6,7 Subsequent prospective com-
munity-based accrual of >3,000 probands over 12 years
revealed that ~25% of individuals who met the diagnostic
criteria harbored germline pathogenic PTEN mutations.8
Relatedly, we note that many individuals show clinical
features reminiscent of CS but do not meet the ICC
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Relevant to clinical practice, we generated a predictive
PTEN risk calculator8 that evaluates the pretest probability
that an individual harbors a deleterious germline PTEN
mutation on the basis of key clinical features.8 The resul-
tant score is known as the PTEN Cleveland Clinic score,
or CC score. A CC score of 10, corresponding to a pretest
probability of >3% and a sensitivity of 90%, is recommen-
ded as a threshold for referring adult CS or CSL individuals
for PTEN mutational testing and further genetic assess-
ment. However, many CS and CSL individuals evaluated
in clinic have high CC scores (range 10–54) and no under-
lying germline PTEN mutations or large deletions, indi-
cating high phenotypic burden independent of PTEN
and, hence, a high likelihood that other susceptibility
genes exist. Indeed, we have so far reported that within
this PTEN-mutation-negative subset of CS and CSL indi-
viduals, up to 8% harbor germline variants in mitochon-
drial complex II subunit genes SDHB (MIM: 185470),
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to 30% have promoter hypermethylation in tumor-
suppressor gene KLLN (MIM: 612105),11 and 11% have
germline AKT1 (MIM: 164730) or PIK3CA (MIM: 171834)
gain-of-function mutations.12
Epithelial thyroid carcinomas (both papillary and follic-
ular histologies) are a major component of CS.13 We have
shown in a prospective series of 2,723 CS and CSL indi-
viduals that germline mutations in a subset of the estab-
lished susceptibility genes (PTEN, SDHB, SDHC, SDHD,
and KLLN) increase the risk of epithelial thyroid cancer
by at least 45-fold in comparison to the risk in the US gen-
eral population.14 Moreover, included in our series of CS
individuals are PTEN-mutation-positive probands diag-
nosed under the age of 18 years (the earliest age at diag-
nosis was 7 years), reflecting a strong genetic component
in the etiology of thyroid cancer. In support of these find-
ings, epidemiological studies have reported that thyroid
cancers show a high index of ‘‘familiality’’ among all solid
tumors.15,16 However, the hunt for candidate genes associ-
ated with familial thyroid cancer continues today, and
there is an increased appreciation for the heterogeneity
of the disease and the contribution of hereditary predispo-
sition and the micro- and macro-environment to tumor
pathobiology.17 In this context, not only would additional
CS-relevant genes serve as candidates for apparently spo-
radic predisposition to epithelial thyroid cancer, but their
identification would also improve molecular diagnosis,
especially predictive testing, cancer risk assessment, ge-
netic counseling, and clinical management in CS and
CSL. Therefore, we sought to identify previously unde-
scribed cancer-predisposing gene(s) in CS and CSL via
an approach combining exome sequencing and family
studies and, subsequently, to characterize the functional
consequence.Material and Methods
Research Participants and Clinical Data
We scanned our clinical database for accrued CS- and CSL-
affected families. Eligible families consisted of at least one unaf-
fected and two affected family members. Eligible probands tested
negative for germline mutations in PTEN, SDHB, SDHC, SDHD,
AKT1, and PIK3CA and met at least the relaxed ICC operational
diagnostic criteria (Table S1). Relaxed criteria are defined as full
criteria minus one, and such individuals are referred to as having
CSL.7
For all selected individuals, we reviewed the CC score, a semi-
quantitative score that is based on weighting clinical features
and that estimates the pretest probability of finding a germline
PTEN mutation (see Web Resources).8 Given that all individuals
are wild-type for PTEN, we used the CC score as a surrogate of
phenotypic burden. We hence targeted probands with a high
CC score and eligible family members with available blood
samples for genetic testing. We reviewed medical records,
including pathology reports, for each research participant and
extracted family history from clinical notes associated with can-
cer genetics and/or genetic-counseling visits, where applicable
and with the individuals’ consent. Cleveland Clinic Institu-662 The American Journal of Human Genetics 97, 661–676, Novembtional Review Board approval (protocol 8458) and informed
consent from all research participants were obtained for this
study.Exome Sequencing and Bioinformatic Analysis
We subjected germline genomic DNA extracted from peripheral-
blood leukocytes of the eligible proband to exome sequencing.
Exome enrichment was performed with the TruSeq SBS v.3 Kit
(Illumina), and subsequent 100 bp paired-end sequencing was
performed with an Illumina HiSeq 2000 platform. Sequencing
was performed at an Illumina Sequencing Service Center.
Raw sequencing reads were mapped to the human reference
haploid genome sequence (UCSC Genome Browser hg19) with
the Burrows-Wheeler Aligner (BWA v.0.6.1).18 Insertion or dele-
tion (indel) realignment, base- and quality-score recalibrations,
and removal of PCR duplicates from the resultant binary align-
ment map (BAM) files were performed with the Genome Analysis
Toolkit (GATK),19,20 Sequence Alignment/Map (SAMtools), and
Picard.21 Variant discovery and genotype calling of single-nucleo-
tide variations (SNVs) and short (<50 bp) indels were performed
with the GATK Haplotype Caller.Variant Filtration and Annotation
To prioritize causal variants, we applied the ANNOVAR Variants
Reduction pipeline.22 First, we discarded synonymous variants
and intronic variants more than 2 bp from exon boundaries. We
retained variants in conserved genomic regions on the basis of a
46-species alignment and removed variants existing in segmental
duplication regions. We excluded variants with a minor allele fre-
quency (MAF)R 0.0005 in the 1000 Genomes Project (April 2012
release) or the NHLBI Exome Sequencing Project (ESP) Exome
Variant Server (ESP6500 dataset) and variants reported in the
dbSNP137 non-flagged database (excluding clinically associated
SNPs).
To predict the potential impact of missense variants on pro-
tein function, we used the program Consensus Deleteriousness
(Condel v.1.5),23 which combines multiple prediction software
algorithms (SIFT,24 PolyPhen-2,25 and MutationAssessor26)
into a single weighted score. We inspected all resultant vari-
ants through the Integrative Genomics Viewer (IGV).27,28 We
also used an in-house database containing variants from 11 in-
dividuals with sporadic polyposis and 13 exomes from individ-
uals with unrelated phenotypes (connective-tissue disorders);
these were sequenced with our cohort of research participants
as an additional internal control filter. We excluded variants
that appeared more than once in these in-house exome
databases.Mutation Validation
Mutations in candidate genes of interest were validated by
PCR-based region-specific mutation analysis through Sanger
sequencing. In brief, gene-specific primers encompassing exonic
regions harboring the particular variations were designed. Seq-
uencing was performed in the forward and reverse directions
with Applied Biosystems ABI 3730xl DNA Analyzers at the Geno-
mics Core of the Lerner Research Institute of the Cleveland Clinic
and the Eurofins Genomics DNA-sequencing facility (Louisville).
Resultant chromatograms were analyzed with Mutation Surveyor
DNA Variant Analysis Software (SoftGenetics), and mutations
were reported according to the Human Genome Variation Society
(HGVS) guidelines. Incidental findings were reported to ourer 5, 2015
genetic counselors to be communicated to the respective affected
individuals and physicians of record according to the ACMG
guidelines.29 Confirmed variants were sequenced in all recruited
family members regardless of disease status.
Variant Interpretation and In Silico Pathogenicity
Predictions
Variants retained after prioritization were considered potentially
pathogenic. Importantly, prioritized variants had to be shared in
all affected members of the pedigree. Further prioritization was
performed on the basis of the relation of the genes to the clinical
phenotypes (where applicable), predicted loci of the mutations
affecting functional protein domains, and in silico assessment of
the mutations’ effect on protein integrity through a combination
ofmutation-prediction algorithms, namely Condel,23 SIFT,24 Poly-
Phen-2,25 MutationTaster,30 MutPred,31 and Combined Annota-
tion Dependent Depletion (CADD).32
Prioritized candidate genes resulting from pedigree analysis
were then screened in an independent series of 96 CS and/or
CSL probands who were negative for germline mutations in
PTEN, SDHB, SDHC, and SDHD and who had overlapping clinical
phenotypes with those observed in the pedigree under study
(mainly thyroid, breast, and endometrial cancers). Gene-specific
primers were designed for all exons, and Sanger sequencing was
performed as stated above.
The accession numbers for theC16orf72, PTPN2, and SEC23B se-
quences reported in this paper are GenBank: NM_014117.2,
NM_080422.2, and NM_001172745.1, respectively.
TCGA Germline Variants Dataset Analysis
We analyzed The Cancer Genome Atlas (TCGA) datasets on papil-
lary thyroid carcinoma (THCA, n ¼ 494) and a subset of breast
invasive carcinoma (BRCA, n ¼ 222) and uterine corpus endome-
trioid carcinoma (UCEC, n ¼ 156). We analyzed all tumors with
sequenced adjacent normal tissue or blood for analysis of germline
mutations. Germline mutations were extracted and analyzed from
raw sequencing data. In brief, genomic loci corresponding to
candidate genes were extracted from the aligned BAM files, and
a MAF % 0.01 was used for filtering variants through dbSNP137,
1000 Genomes, and ESP6500. Mutation predictions were obtained
from SIFT,24 PolyPhen-2,25 and MutationTaster.30 Importantly, we
visualized and manually curated all mutations through the
IGV27,28 to confirm that they indeed exist in the tumor and adja-
cent normal tissue and/or blood and are hence in the germline.
Corresponding clinical data were obtained from the TCGA Data
Portal Matrix.
Predicted Structural Effects of Variants
We predicted the structural effects of variants by using the HOPE
server, which integrates a series of standard algorithms to generate
predictions.33 Because the Homo sapiens SEC23B crystal structure
has not been resolved, the crystal structure of the human
SEC23A-SEC24A heterodimer, complexed with the SNARE protein
SEC22B34 (PDB: 2NUP), was identified as a modeling template for
predicting structural effects.
Cell Lines and Culture Conditions
Immortalized lymphoblastoid cell lines (LCLs) derived from
affected individuals or normal control individuals were generated
by the Genomic Medicine Biorepository of the Genomic Medicine
Institute of the Cleveland Clinic according to standard proceduresThe Americanand were subsequently maintained in RPMI-1640 supplemented
with 20% fetal bovine serum (FBS) and 1% penicillin and strepto-
mycin. HEK293T cells (originally purchased from the American
Type Culture Collection) in 2011 and obtained in 2014 from the
Cleveland Clinic Lerner Research Institute Cell Culture Core)
were cultured in DMEM supplemented with 10% FBS and 1%
penicillin and streptomycin. The Nthy-ori 3-1 human thyroid
follicular epithelium cell line (catalog no. EC90011609, lot no.
09C008, passage no. 16, purchased in 2014 from Sigma) was
cultured in RPMI-1640 supplemented with 2 mM glutamine and
10% FBS. All cell lines were maintained at 37C and 5% CO2 cul-
ture conditions and tested negative upon routine mycoplasma
testing with the MycoAlert Mycoplasma Detection Kit (Lonza) at
the C.E. lab (luminescence ratios < 0.9). Cell lines used have not
been listed as cells known to be misidentified according to the
International Cell Line Authentication Committee.35 The Nthy-
ori 3-1 cell line was authenticated through short-tandem-repeat
PCR (AmpFLSTR SGM Plus PCR Amplification Kit, Life Technolo-
gies) by the European Collection of Cell Cultures (original source
of the cell line, test date April 14, 2009).
RNA Extraction and qRT-PCR
RNA was extracted from LCLs derived from affected and unaf-
fected individuals with the RNeasy Mini Kit (QIAGEN), purified
with Turbo DNase treatment (Life Technologies), and reverse tran-
scribed with Superscript III Reverse Transcriptase (Life Technolo-
gies). Primers were designed for gene transcripts of interest, and
cDNAwas quantified with SYBR Green (Life Technologies). Results
were analyzed by the standard DDCT method.
Immunoblotting
Proteinwas extracted fromwhole-cell lysates with theMammalian
Protein Extraction Reagent M-PER (Thermo Scientific Pierce) sup-
plemented with a cocktail of protease and phosphatase inhibitors
(Sigma-Aldrich) and was quantified with the BCA Protein Assay Kit
(Thermo Scientific Pierce). Lysates were separated by SDS-PAGE
and transferred onto nitrocellulose membranes. We probed for
anti-SEC23B rabbit polyclonal (Abcam ab151258) at 1:1,000, for
anti-SEC23A rabbit polyclonal generated against synthetic pep-
tides (CQKFGEYHKDDPNSFRFSET and DNAKYVKKGTKHFEA)36
at 1:2,000, and for anti-GAPDH rabbit monoclonal (Cell Signaling
2118) at 1:20,000 dilutions. Blots were scanned digitally and
quantified with the Odyssey Infrared Imaging System (Li-Cor
Biosciences).
Plasmids, Mutagenesis, and Cell-Line Transfection
and Transduction
GFP- and FLAG-tagged wild-type SEC23B plasmids (pMSCV and
pEGFP-C3 vectors, respectively) were used.36 Wild-type plasmids
were mutagenized for the missense mutation of interest with
the QuikChange II Site-Directed Mutagenesis Kit (Agilent Tech-
nologies). All expression constructs were validated by Sanger
sequencing prior to transfection or transduction. For transient
overexpression, cell lines were transfected with Lipofectamine
3000 reagent (Invitrogen) according to the manufacturer’s instruc-
tions. Fresh media replaced the transfection media 5 hr after
transfection. Cells were grown for at least 24 hr before harvesting.
To generate stable cell lines, we kept retrovirally transduced cells (a
pool, given that no individual clones were isolated) under 1 mg/ml
puromycin selection for >30 days prior to downstream interroga-
tion. We used four different pools of cells at passage no. 28 afterJournal of Human Genetics 97, 661–676, November 5, 2015 663
selection. All experiments were conducted with cells at passage
nos. between 29 and 42.
Immunofluorescence
Cells were seeded on coverslips and were fixed with 4% parafor-
maldehyde for 10 min at room temperature. Coverslips were
mounted with ProLong Gold Antifade mountant with DAPI (Invi-
trogen). Slides were visualized and images were obtained with a
TCS SP5 confocal microscope (Leica).
Immunoprecipitation
Cells were pelleted after transfection and lysed with M-PER
(Thermo Scientific Pierce) supplemented with a cocktail of prote-
ase and phosphatase inhibitors (Sigma-Aldrich). Protein lysates
were collected by centrifugation at 13,000 RPM for 15 min at
4C and pre-cleared by incubation with protein A/G PLUS-Agarose
immunoprecipitation reagent (Santa Cruz sc-2003) for 30 min
at 4C on a rotator. Pre-cleared protein lysates were quantified
with the BCA Protein Assay Kit (Thermo Scientific Pierce), and
1 mg/ml lysates were prepared. We used anti-SAR1A (Santa Cruz
sc-130463) and anti-DDK (Origene 4C5) antibodies for pull-
down and immunoblotting at the recommended dilutions.
Doubling Time and Cell Viability
Cells were trypsinized, homogenized, and counted with the
Countess Automated Cell Counter (Invitrogen). We used Trypan
blue to account for dead cells and to assess cell viability. We also
used the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) assay (Sigma) to assess cell viability according to
the manufacturer’s instructions.
In Vitro Migration and Invasion Assays
Transiently transfected cells were grown for 48 hr, and a migration
assaywasperformedaccording toLianget al.,37with theminorvari-
ation of creating scratches on the cell monolayer with a p10 pipet
tip.Migrationof the stable cell lineswasassessedwith6.5mmtrans-
wells and 8.0 mmpore polycarbonate membrane inserts (Corning).
Invasion was assessed with BioCoat Matrigel invasion chambers
and8.0mmpolyethylene terephthalate (PET)membrane (Corning).
Cells were serum starved for 24 hr and harvested with the HyClone
HyQTase Cell Detachment Reagent (GE Healthcare). For both
assays, 5 3 104 cells were seeded in the upper chambers in serum-
starved media. The lower chambers were filled with complete
growth media supplemented with 10% FBS; however, for back-
ground correction sets, both chambers were filled with serum-
starved media. Migration and invasion experiments proceeded for
24 hr. Cells that migrated or invaded were fixed with 4% parafor-
maldehyde for 5 min, permeabilized with 100% methanol for
20 min, and stained with Giemsa for 15 min all at room tempera-
ture. Cells were photographed under 103 magnification and
counted in quadruplicate fields of view in triplicate membranes.
SDS-PAGE Zymography
Cells were serum starved for 24 hr, and conditioned media were
collected and concentrated with spin columns with a 10 kDa mo-
lecular-weight cutoff (Biovision). Protein concentrations were
determined with the BCA Protein Assay Kit (Thermo Scientific
Pierce). Equal volumes of sample and zymogram sample buffer
(Bio-Rad) were mixed and loaded on 10% gelatin zymogram gels
(Bio-Rad). After electrophoresis, gels were washed with renatur-
ation buffer (Bio-Rad), incubated for 18 hr at 37C in developing664 The American Journal of Human Genetics 97, 661–676, Novembbuffer (Bio-Rad), and stained for 2 hr with Coomassie Brilliant
Blue R-250 staining solution (Bio-Rad). Enzymatic activity was
visualized as a colorless band against the Coomassie blue back-
ground. Bands were quantified with Image J software (NIH), and
values were normalized to total protein.
ER-Stress Induction and Assessment of Cell Viability
and Colony Formation
Cells were seeded and allowed to grow overnight and then treated
with either 1 mM thapsigargin or 0.1 mg/ml tunicamycin (Sigma-
Aldrich). Cells were checked every day for colony formation
and cell number, and viability was assessed through Trypan
blue staining. At the respective drug-treatment endpoints,
cells were fixed with 70% ethanol for 5 min at room temperature
and stained with Giemsa (Sigma-Aldrich). Colonies (defined as
clusters of R50 cells) were counted with the use of a microscope
(33 magnification).38
Statistical Analyses
Sample-size power was calculated with OpenEpi software (seeWeb
Resources); a population size of 1,000,000 individuals and a
hypothesized percent frequency of outcome factor (SEC23B-
variant-positive status) of 2% 5 5% were used. The sample size
(n) was predicted for various confidence levels (80%–99.99%).
Standardized incidence rate (SIR) for thyroid cancer is a sum-
mary ratio that allows comparison of incidence rates of thyroid
cancer between affected (variant-positive) individuals and the
general population. The expected number of thyroid cancers was
obtained with the use of age-specific Surveillance Epidemiology
and End Results (SEER) incidence rates from 2008 to 2012. There
were 19 categories based on two genders and 19 age groups. Inci-
dence was assumed to be zero for categories where statistics were
not provided. Years of observation time per person (person-years
of observation) were calculated from the date of birth to the date
of cancer diagnosis for individuals who developed thyroid cancer
or to the date of most recent information for individuals without
cancer. We calculated the expected number of cancers by multi-
plying SEER incidence rates in each of the 19 categories by per-
son-years of observation in each category. OpenEpi software was
used for calculating SIR. The 95% confidence interval (CI) and cor-
responding p valuewere calculated with themid-p exact test. A SIR
> 1.0 implies that the incidence rate is greater for the population
of interest than for the standard population. For analyses between
affected population groups, we used 2 3 2 tables to calculate the
odds ratio (OR) and 95% CI and used the mid-p exact test to calcu-
late corresponding p values.
Experimental data between wild-type and mutant cell lines are
given asmeans5 SEM, and n corresponds to the number of exper-
iments performed. Student’s t test was used for significance testing
as indicated in the figure legends. All statistical tests were two
sided, and p values% 0.05 were deemed significant.Results
Exome Sequencing and Targeted Genotyping
Identifies SEC23B as a Candidate Gene in a CS-
Affected Family with Predominant Thyroid Cancer
We identified a multi-generation CS-affected family (fam-
ily 616) presenting with different types of CS-related can-
cers, particularly thyroid cancer, across four generations.er 5, 2015
Figure 1. Pedigree of CS-Affected Fam-
ily 616
The pedigree of CS-affected family 616 is
shown with the presence of wild-type ()
or c.1781T>G (p.Val594Gly) mutant (þ)
SEC23B alleles. Symbols are as follows:
square, male; circle, female; black fill,
affected; slash, deceased. The proband
(III-2) for whom whole-exome sequencing
was performed is indicated by an arrow.
Roman numerals represent generation
number, and Arabic numerals represent in-
dividuals within each generation. Affected
members show various types of CS-related
cancers, including thyroid (II-4, III-2, III-4,
and IV-1), breast (II-2 and II-3), endome-
trial (IV-4), skin (III-5), and both thyroid
and breast (I-4) cancers. Age at diagnosis
is indicated between parentheses. Abbrevi-
ations are as follows: TC, thyroid cancer;
BT, benign thyroid; BC, breast cancer; EC,
endometrial cancer; SC, skin cancer.The family pedigree suggests autosomal-dominant inheri-
tance with complete penetrance (Figure 1). The proband
(III-2) is a 60-year-old female who presented at our CS
clinic with follicular variant papillary thyroid cancer
(FvPTC; diagnosed at age 43), goiter, breast fibroadenoma
and papilloma, typical breast ductal hyperplasia, fibro-Table 1. Characteristics of the Three Candidate Variants Identified in
Genes
SEC23B
Genomic positiona chr20: 18,529,290
DNA variant c.1781T>G
Protein alteration p.Val594Gly
Predicted Effect of Missense Variants
Condelb deleterious
MutationTaster disease causing
MutPred g score (>0.5) 0.785
CADD scorec 22.2
Evolutionary Conservation and Allele Frequency
PhyloPd 4.572
PhastConse 1
NHLBI ESPf MAF G ¼ 0, T ¼ 13,006
Tissue-Specific Protein Levelsg
Thyroid þ
Breast þ
Endometrium þ
aGenomic positions correspond to the UCSC hg19 reference assembly.
bCondel combines multiple prediction software algorithms (SIFT, PolyPhen-2, an
cCADD-scaled C score R 20 indicates variants within the top 1% of likely deleter
dPhyloP scores range between 14 and þ6; conserved sites have positive scores.
ePhastCons scores range between 0 and 1; values closer to 1 have a higher proba
fNHLBI Exome Sequencing Project (ESP) Exome Variant Server (see Web Resource
gData analyzed from the Human Protein Atlas for immunohistochemically stained
The Americancystic breast disease, trichilemmoma, papillomatous pap-
ules of the mucosa, gastrointestinal polyps, and uterine
fibroids. The individual had a high CC score of 16, but
importantly, analyses for PTEN intragenic mutations and
deletions revealed a wild-type sequence. This suggested
a high phenotypic burden independent of PTEN, andAffected Members of Family 616
C16orf72 PTPN2
chr16: 9,186,804 chr18: 12,794,321
c.253T>C c.1204G>A
p.Ser85Pro p.Ala402Thr
deleterious deleterious
disease causing polymorphism
0.525 0.578
23.2 9.28
2.882 1.282
1 0.994
C ¼ 0, T ¼ 12,994 T ¼ 0, C ¼ 13,006
 þ
 þ
 þ
d MutationAssessor).
ious variants across the human genome.
bility of nucleotide conservation.
s) v.0.0.28 (accessed May 9, 2015).
normal and cancer tissues.
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Table 2. Genotype and Clinical Phenotype of Known Mutation-Negative CS and/or CSL Individuals with Germline SEC23B Variants
Probands
CCF02565 CCF05664 CCF04372
Age 59 years 69 years 51 years
Sex female female female
CC score 7 11 14
Clinical features FvPTC (age 52 years),
macrocephaly
PTC (age 45 years), ductal carcinoma in situ,
atypical ductal hyperplasia, fibrocystic breast
disease, hemangioma, macrocephaly
PTC (age 45 years), goiter, Hashimoto thyroiditis,
macrocephaly
SEC23B variant c.490G>T (p.Val164Leu),
rs36023150
c.490G>T (p.Val164Leu),
rs36023150
c.1512T>C (p.¼),
near splice,
rs138198461
NHLBI ESP MAF T ¼ 97, G ¼ 12,909 (0.0075) T ¼ 97, G ¼ 12,909 (0.0075) C ¼ 52, T ¼ 12,954 (0.0040)
SIFT damaging (0.01) damaging (0.01) –
PolyPhen-2 possibly damaging (0.87) possibly damaging (0.87) –
MutationTaster disease causing disease causing disease causing (acceptor lost)
PhyloPa 5.615 5.615 –
PhastConsb 1 1 –
Abbreviations are as follows: FvPTC, follicular variant papillary thyroid cancer; PTC, papillary thyroid cancer.
aPhyloP scores range between 14 and þ6; conserved sites have positive scores.
bPhastCons scores range between 0 and 1; values closer to 1 have a higher probability of nucleotide conservation.subsequent testing also showed no germline mutations or
deletions in SDHB, SDHC, or SDHD and the absence of
KLLN hypermethylation. We therefore recruited the pro-
band for our whole-exome sequencing efforts to identify
previously unidentified candidate genes in mutation-
negative CS individuals with high CC scores. Exome
sequencing of germline genomic DNA derived from III-2
achieved a mean coverage of 96.33, and >90% of the tar-
geted regions were covered by at least ten reads. Filtering
the gene variants through ANNOVAR22 and Condel23
and subsequent manual curation through the IGV27,28 re-
tained 44 potentially deleterious gene variants, of which
39 were validated by Sanger sequencing (Table S2).
To identify candidate cancer-predisposing CS-related
genes segregating in the proband’s family, we applied
Sanger sequencing for the 39 validated gene variants in
seven other family members with available DNA (II-3,
III-3, III-4, IV-1, IV-3, IV-4, and IV-5). Four (II-3, III-4,
IV-1, and IV-4) met CS diagnostic criteria and presented
with different cancer types, whereas the remaining three
(III-3, IV-3, and IV-5) had no apparent phenotypes. Upon
variant filtration (Table S2), all affected members were
found to share three genes with heterozygous missense
variants: C16orf72 (c.253T>C [p.Ser85Pro]), PTPN2
(c.1204G>A [p.Ala402Thr]), and SEC23B (c.1781T>G
[p.Val594Gly]). Notably, no variants were noted in PTEN,
SDHB, SDHC, SDHD, KLLN, PIK3CA, or AKT1. The three
variants in SEC23B, C16orf72, and PTPN2 have not been
reported in public databases (dbSNP137, 1000 Genomes,
or ESP6500). We examined in silico the predicted func-
tional impact of these prioritized variants and noted a
higher index of pathogenicity for the SEC23B variant ac-666 The American Journal of Human Genetics 97, 661–676, Novembcording to multiple mutation prediction databases and
multi-species evolutionary amino acid residue conserva-
tion (Table 1). We next inspected the protein status of
the prioritized genes in tissues of interest through the Hu-
man Protein Atlas.39,40 We found that only PTPN2 and
SEC23B are expressed in thyroid, breast, and/or endome-
trial normal and cancer tissues (organs affected in family
616). However, given that the PTPN2 variant was predicted
as the least damaging and annotated as a ‘‘polymorphism’’
by MutationTaster, the combined in silico data indicate
that the SEC23B variant is the most critical germline
variant in family 616 (Figure S1).
Germline Heterozygous SEC23B Variants Exist in
Unrelated CS Probands with Thyroid Cancer
We next sought to investigate whether germline variants in
SEC23B and the other two prioritized genes exist in other
CS individuals. We selected 96 CS and CSL probands
with either a diagnosis of thyroid cancer or signs of other
cancers observed in family 616, namely breast and endome-
trial carcinomas (Table S3). This sample size gave us >95%
power to detect a 2% prevalence of variants. We directly
sequenced all exons of SEC23B, PTPN2, and C16orf72. We
found deleterious germline heterozygous SEC23B variants
in three probands (3.1%). Papillary thyroid cancer (PTC)
was found in all three individuals, one of whom showed
the follicular variant on histology. Interestingly, two indi-
viduals had the same missense SEC23B variant (c.490G>T
[p.Val164Leu]) affecting a highly evolutionarily conserved
residue within the SEC23B trunk domain,41 and all three
variants we found are rare in the general population and
predicted to be damaging (Table 2). In support of ourer 5, 2015
Table 3. Characteristics of Germline SEC23B Variants in TCGA Thyroid, Breast, and Endometrial Cancer Datasets
Cancer Datasets Variants NHLBI ESPa MAF SIFT PolyPhen-2 MutationTaster
Conservation
Phylob PhastConsc
THCA (n ¼ 494) c.1661G>A (p.Arg554Gln) 0 damaging (0.02) probably damaging (0.998) disease causing 5.365 1
c.1598T>G (p.Val533Gly) 0 damaging (0) possibly damaging (0.621) disease causing 4.497 1
c.167A>G (p.Tyr56Cys) 0 damaging (0) possibly damaging (0.752) disease causing 4.798 1
c.301A>G (p.Ile101Val) 0 damaging (0.04) possibly damaging (0.643) disease causing 4.760 1
c.689þ1G>C 0 – – disease causing 5.047 1
c.2101C>T (p.Arg701Cys) 0 damaging (0) probably damaging (1.000) disease causing 2.648 0.988
c.1636C>T (p.Arg546Trp) T ¼ 1, C ¼ 13,005 (0.000077) damaging (0) probably damaging (1.000) disease causing 1.987 1
c.2031G>A (p.Met677Ile) A ¼ 2, G ¼ 13,004 (0.000154) damaging (0.02) benign (0.014) disease causing 5.584 1
c.40C>T (p.Arg14Trp) T ¼ 3, C ¼ 13,003 (0.000231) damaging (0.01) probably damaging (0.999) disease causing 2.132 1
c.1484G>A (p.Arg495His) A ¼ 95, G ¼ 12,911 (0.007358) tolerated (0.12) probably damaging (0.961) disease causing 5.579 1
c.490G>T (p.Val164Leu) T ¼ 97, G ¼ 12,909 (0.0075) damaging (0.01) possibly damaging (0.870) disease causing 5.615 1
BRCA (n ¼ 222) c.884C>A (p.Pro295His) 0 damaging (0) probably damaging (0.983) disease causing 5.778 1
c.985G>T (p.Ala329Ser) T ¼ 4, G ¼ 13,002 (0.000307) damaging (0.04) possibly damaging (0.601) disease causing 5.591 1
c.74C>A (p.Pro25His) A ¼ 5, C ¼ 13,001 (0.000385) damaging (0) probably damaging (1.000) disease causing 5.701 1
c.490G>T (p.Val164Leu) T ¼ 97, G ¼ 12,909 (0.0075) damaging (0.01) possibly damaging (0.870) disease causing 5.615 1
UCEC (n ¼ 156) c.389T>C (p.Ile130Thr) 0 damaging (0.05) benign (0.006) disease causing 4.638 1
c.649C>T (p.Arg217*) T ¼ 1, C ¼ 13,005 (0.000077) – – disease causing 0.056 0.031
c.490G>T (p.Val164Leu) T ¼ 97, G ¼ 12,909 (0.0075) damaging (0.01) possibly damaging (0.870) disease causing 5.615 1
aNHLBI Exome Sequencing Project (ESP) Exome Variant Server v.0.0.28 (accessed May 9, 2015).
bPhyloP scores range between 14 and þ6; conserved sites have positive scores.
cPhastCons scores range between 0 and 1; values closer to 1 have a higher probability of nucleotide conservation.
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Figure 2. Germline SEC23B Mutation Spectra in CS and Apparently Sporadic CS-Related Cancers from TCGA
A schematic of SEC23B and its functional domains is shown; Arabic numerals correspond to amino acid number. The amino acid posi-
tions corresponding to germline heterozygous variants are indicated for variants identified in CS-affected family 616 (blue), an unrelated
CS proband (gray), TCGA apparently sporadic thyroid cancer (black), breast cancer (pink), endometrial cancer (purple), and a shared
variant observed in all three cancer types and in CS (green). Abbreviations are as follows: ZNF, zinc finger domain; BS, beta-sandwich.in silico gene prioritization, no germline variants were
found in C16orf72 or PTPN2 in the 96 unrelated CS and
CSL probands.
Germline Heterozygous SEC23BVariants Are Enriched
in Apparently Sporadic Thyroid Cancer and Associate
with Early Age of Onset
To determine whether SEC23B is associated with apparently
sporadic cancers, we next analyzed the spectrum and
frequencies of germline variants in three TCGA CS-compo-
nent cancers (also observed in family 616): papillary thy-
roid (n¼ 494), breast invasive (n¼ 222), and uterine corpus
endometrioid (n ¼ 156) carcinomas. Indeed, we found
germline heterozygous variants in all three studied cancer
types, and the highest frequency (4%) was observed in thy-
roid cancer. Furthermore, we observed an overrepresenta-
tion of unique SEC23B variants in thyroid cancer (Table
3). All variants we found are predicted to be deleterious
and have various protein structural effects (Table S4). For
affirmation, we also inspected C16orf72 and PTPN2 and
observed the absence ofmutations ormuch lowermutation
frequencies in the three cancer types (Table S5). Although
we used a small sample size, we calculated the age-adjusted
SIR of thyroid cancer in SEC23B-variant-positive TCGA in-
dividuals (n ¼ 19) and found that it is significantly higher
than in the US general population (SIR ¼ 242.6; 95%
CI ¼ 150.4–371.8; p ¼ 1.0 3 1011). Relatedly, the median
age at diagnosis of thyroid cancer is younger for SEC23B-
variant-positive individuals, especially for those with
unique variants, than for the entire TCGA thyroid cancer
cohort (36 versus 46 years, p ¼ 0.025). One such indi-
vidual who was diagnosed with PTC at age 21 had a
parent with thyroid cancer. Lastly, three unrelated indi-
viduals harbored the same SEC23B variant (c.1598T>G
[p.Val533Gly]) affecting the helical SEC23B domain, where
the p.Val594Gly variant from family 616 also occurs. The
spectrum of germline SEC23B variants in CS and TCGA
CS-related cancers is depicted in Figure 2.42
Our findings indicate that both unique andpreviously re-
ported (0.00008%MAF%0.008) germline SEC23B variants
exist in CS individuals and in the studied individuals with
sporadic cancer. This prompted us to investigate the fre-
quency of heterozygous SEC23B variants in individuals668 The American Journal of Human Genetics 97, 661–676, Novembwith no reported cancer diagnoses.We analyzed the NHLBI
exomes representing 2,203 African-American and 4,300
European-American unrelated individuals, totaling 13,006
chromosomes. We found deleterious SEC23B variants in
155 (1.2%; MAF % 0.008) or 58 (0.45%; MAF % 0.0004)
chromosomes (Table S6). In comparison, the studied
TCGA populations with apparently sporadic cancer show
deleterious SEC23B variants in 29 (1.7%; MAF% 0.008) or
16 (0.93%; MAF % 0.0004) out of 1,744 chromosomes.
Interestingly, this comparison yields a significantly higher
OR for thyroid cancer in TCGA populations than in NHLBI
populations, especially for variants with a MAF % 0.0004
(OR ¼ 2.5; 95% CI ¼ 1.3–4.7; p ¼ 0.0116) (Table S7).
Functional Characterization of p.Val594Gly in Family
616 Reveals a Tumorigenic Cellular, Molecular, and
Biochemical Phenotype
SEC23B is a component of COPII vesicles for anterograde
ER-to-Golgi transport.43,44 Recessive loss-of-function mu-
tations cause congenital dyserythropoietic anemia type II
(CDAII),45,46 resulting in decreased SEC23B levels.45,47,48
Available clinical laboratory results from a subset of the
available heterozygous SEC23B-variant-positive CS indi-
viduals were not suggestive of a classic CDAII phenotype,
and reports signed off as ‘‘normal’’ for most of these indi-
viduals (Table S8). Also, lymphoblastoid cells derived
from family 616 showed no differences in SEC23B tran-
script and protein levels between variant carriers and
wild-type individuals (Figure 3), suggesting that a probable
change in function rather than reduced SEC23B levels (loss
of function) is the likely mechanism in CS.
We then sought to functionally characterize the unique
deleterious SEC23B variant (c.1781T>G [p.Val594Gly])
found in family 616. We transiently transfected HEK293T
cells with wild-type and p.Val594Gly SEC23B. Mutant cells
revealed aberrant aggregation of SEC23B and signifi-
cantly increased cell migration and upregulation of epithe-
lial-to-mesenchymal transition (EMT) genes, suggesting a
cancer-relevant phenotypic effect (Figure S2). Notably,
the p.Val594Gly variant occurs between the alpha-N and
alpha-M regions within the SEC23B helical domain
critical for binding to SAR1,49 a GTPase activated by
SEC23 and another component of the inner coat of COPIIer 5, 2015
Figure 3. Lymphoblastoid Cells Derived from Family 616 Show
No Differences in SEC23B Transcript and Protein Levels between
p.Val594Gly Carriers and Wild-Type Individuals
(A) qRT-PCR expression showed no notable trend in SEC23B
transcript expressionbetweenwild-type individuals andvariant car-
riers. Values are normalized to unaffected individual III-3 and repre-
sent three technical replicates for which data representmean values
5 SEM. **p < 0.01, *p < 0.05 (two-sided Student’s t test).
(B) SEC23B levels and quantification by western blot. PTEN-muta-
tion-positive lymphoblastoid cells (LCLs) from other CS individ-
uals were also used as internal exploratory controls. 1019XX,
1202XX, and 4406XX represent healthy control LCLs unrelated
to the pedigree.
SEC23B-mutation carriers from the pedigree are indicated by aster-
isks in each panel. ‘‘aa’’ refers to the amino acids targeted by the
SEC23B antibody.vesicles. We speculated that the observed alteration might
affect binding of SEC23B to SAR1A and confirmed this
through immunoprecipitation of tagged SEC23B and
SAR1A in 293T-SEC23B-WT and 293T-SEC23B-V594G
cells (Figure S3). Pertinent to the cancer type (i.e., thyroid)
enriched in family 616 and TCGA, we then generated sta-
ble normal thyroid follicule epithelial50 cell lines express-
ing wild-type or p.Val594Gly SEC23B (Nthy-SEC23B-WT
or Nthy-SEC23B-V594G, respectively). We validated that
compared to Nthy-SEC23B-WT and Nthy-SEC23B-E109K
cells (the latter of which represents one of two CDAIIThe Americanfounder mutations accounting for ~50% of reported
cases51,52), the Nthy-SEC23B-V594G cells associated with
the CS-affected family showed aberrant SEC23B aggrega-
tion (Figure 4A and Figure S4). The Nthy-SEC23B-E109K
cells lacked a normal ER expression pattern, supporting
the loss of altered protein in anemia. Relatedly, western
blot analysis revealed similar levels of SEC23B and paralog
SEC23A in wild-type and mutant Nthy-SEC23B-V594G
cells, adding to the evidence that the mutation does not
result in loss of function of SEC23B and does not lead to
concomitant compensation by SEC23A (Figure 4B).53
To our surprise, Nthy-SEC23B-WT and Nthy-SEC23B-
V594G cells showed no differences in growth, viability,
or migration ability (Figure S5). We hypothesized that
another aspect of the EMT phenotype might be affected
in normal thyroid cells, and so we turned our attention
to investigating other EMT-related manifestations (or
phenotypes). Indeed, Transwell invasion assays revealed
a significantly higher (9-fold) increase in Matrigel invasion
(p¼ 2.313 107) in Nthy-SEC23B-V594G cells (Figure 5A).
We then demonstrated through gelatin zymography that
these mutant cells showed increased activity of MMP-2
and MMP-9 (matrix-digesting metalloproteinases) in the
supernatant (Figure 5B), thus explaining the invasive po-
tential of these cells.
We continued to examine other cellular phenotypes
linked to carcinogenesis. Given that loss of SEC23B in
mice causes ER stress and degeneration of secretory or-
gans,36wehypothesized that heterozygous SEC23B variants
might primemutant cells to respond differently to ER-stress
stimuli. We first treated cells with thapsigargin, an ER Ca2þ
ATPase inhibitor conventionally used to induce ER stress
experimentally. Previous studieshave reported that ER stress
can induce an EMT phenotype in thyroid and lung alveolar
epithelial cells.54–56Consistentwith these studies,54–56 start-
ing at 6 hr after treatmentwith thapsigargin, bothwild-type
and mutant cells showed a cellular and molecular pheno-
type consistent with EMT (Figure S6). Intriguingly, cellular
phenotypic differences between wild-type and Nthy-
SEC23B-V594G cells became evident only after chronic
exposure to thapsigargin (at ~14 days) in that mutant cells
formed significantly larger colonies (p ¼ 1.84 3 105) that
survived for up to 36 days after treatment (Figure 5C and
Figure S7). In support of these findings, treatmentwith tuni-
camycin, another standard ER-stress inducer (inhibitor of
proteinN-linkedglycosylation),57 also resulted in the forma-
tion of distinct colonies and conferred an apparent growth
advantage at lower doses in mutant cells (Figure 5D). Over-
all, our experimental findings demonstrate examples of
how a SEC23B germline variant could account for increased
susceptibility to cancer, particularly thyroid cancer.Discussion
Our observations reveal that a subset of CS and CSL
individuals without germline mutations in known genesJournal of Human Genetics 97, 661–676, November 5, 2015 669
Figure 4. Cellular and Biochemical Char-
acterization of Family 616 Variant
p.Val594Gly in a Normal Thyroid Cell Line
(A) Normal thyroid Nthy-ori 3-1 cells were
stably transduced with wild-type and
mutant c.1781T>G (p.Val594Gly) SEC23B
fused with GFP. Wild-type cells (Nthy-
SEC23B-WT) showed SEC23B localization
typical of ER proteins, whereas a subset of
mutantcells (Nthy-SEC23B-V594G) showed
aberrant aggregation of SEC23B. Scale bars
represent 20 mm.
(B) Western blot and densitometric anal-
ysis of overexpressed SEC23B, endogenous
SEC23B and paralog SEC23A, and GAPDH
(loading control) from stable cell lines.
Wild-type and mutant Nthy-SEC23B-
V594G cells showed similar levels of
SEC23B and SEC23A. The Nthy-EGFP cell
line was used as a negative control to indi-
cate baseline levels of SEC23B and SEC23A
in the cell line (no SEC23B overexpression
in these cells). Exogenous SEC23B-GFP
normalized to the wild-type, and endoge-
nous SEC23B and SEC23A normalized to
levels in the Nthy-EGFP cell line.might be accounted for by germline variants in SEC23B. Of
the three SEC23B variants we identified in four unrelated
CS and/or CSL individuals, the pathogenic c.1781T>G
(p.Val594Gly) variant related to family 616 has never
been described before; our functional analyses corroborate
the pathogenicity of this missense mutation. Structurally,
p.Val594Gly occurs between the alpha-N and alpha-M re-
gions within the SEC23B helical domain critical for bind-
ing to SAR1, a GTPase activated by SEC23 and another
component of the inner coat of COPII vesicles. Interest-
ingly, the p.Val164Leu variant present in two other unre-
lated CS and/or CSL individuals occurs within a different
protein domain, the SEC23 trunk domain. This region
forms the dimer interface between SEC23 and SEC24 and
also contacts SAR1,41 suggesting a possible common down-
stream effect. This variant has been reported in ESP6500
with a MAF of 0.0075 (97/12,909). Therefore, although
we cannot ascertain causation, we bear inmind that cancer
is a common phenotypic manifestation even in the gen-
eral population. For example, according to SEER, the risk
of thyroid cancer in the general population is 1%, that
of female breast cancer is 12%, and that of endometrial
cancer is 2.6%.13 Hence, it is possible that this SEC23B
p.Val164Leu variant might be predisposing these individ-
uals to cancer even in the general population.
It is also worth mentioning that SEC23B p.Val164Leu is
reminiscent of two SDHD variants (c.34G>A [p.Gly12Ser]
and c.149A>G [p.His50Arg]) with well-established func-
tional roles in CS and CSL. Although c.34G>A and670 The American Journal of Human Genetics 97, 661–676, November 5, 2015c.149A>G are reported in ESP6500
with a MAF of 0.0080 (103/12,893)
and 0.0063 (82/12,914), respectively,
we have shown that these two vari-ants result in increased reactive oxygen species (via PHD)
and upregulation of p-AKT and p-ERK1/2 (mimicking loss
of function of PTEN).9 Furthermore, they also destabilize
p53 by altering the NAD/FAD ratio, which leads to
decreased NQ01-p53 interaction with consequent non-
MDM2 degradation of p53.10 More recently, we also eluci-
dated that these same SDHD variants lead to nuclear mis-
localization and oxidation of PTEN in CS-related thyroid
cancer.58 Therefore, although SEC23Bmight be a pertinent
cancer-predisposing gene, as demonstrated by our func-
tional evidence of the c.1781T>G (p.Val594Gly) variant,
the relevance of the c.490G>T (p.Val164Leu) variant
would require similar experimental interrogation for
more conclusive evidence, although we believe that the
latter could be a low- to moderate-penetrance allele. Lastly,
because ESP6500 represents a set of population controls, it
is plausible that some individuals might have unrecog-
nized CS and CSL, given the subtlety of some of the clinical
features and the existence of phenotypes often observed in
the general population, such as cancer and non-specific
skin features.
We also found heterozygous germline SEC23B variants
in apparently sporadic breast, thyroid, and endometrial
cancers in TCGA. Notably, these variants were overrepre-
sented in individuals with thyroid cancer and enriched
with unique SEC23B variants predicted to be deleterious
and absent from public databases, suggesting a functional
role in sporadic thyroid carcinogenesis. There is no overlap
of mutation spectra between CDAII52 and CS. However,
Figure 5. The SEC23B c.1781T>G
(p.Val594Gly) Variant Confers Neoplastic
Phenotypes upon ER Stress
(A) Representative images of invaded Nthy-
SEC23B-WT (left) andNthy-SEC23B-V594G
(right) cells in a Transwell assay after over-
night serum starvation. Invaded cells were
counted after 24 hr in quadruplicate fields
of view in triplicate membranes. Data
represent mean values 5 SEM. ***p <
0.001 (two-sided Student’s t test).
(B) Gelatin zymography was performed
with conditioned media from wild-type
and mutant cells and showed more
MMP-2 and MMP-9 activity in supernatant
originating from Nthy-SEC23B-V594G
(right lanes) than in supernatant from
Nthy-SEC23B-WT (left lanes) cells. Data
represent triplicate lanes with band in-
tensity normalized to protein mass. Data
represent mean values 5 SEM. ***p <
0.001, *p< 0.05 (two-sided Student’s t test).
(C)Wild-type andmutant cells were treated
with 1 mM thapsigargin (TG) for the induc-
tion of ER stress. Large colonies of cells ex-
pressing altered SEC23B formed, after
which both Nthy-SEC23B-WT and Nthy-
SEC23B-V594G cells were fixed and stained
with Giemsa, and colonies were counted.
Stained colonies represent cells 14 days af-
ter treatment, and a colony is standardly
defined as a cluster of R50 cells. Data
shown represent three independent experi-
ments done in triplicate for each genotype.
Data represent mean values5 SEM. ***p <
0.001 (two-sided Student’s t test).
(D) Treatment of wild-type and mutant
cells with 0.1 mg/ml tunicamycin (TM),
another ER-stress-inducing agent, resulted
in more growth of mutant cells than
of wild-type cells. Data shown represent
two independent experiments done in
triplicate for each genotype at each
time point. Data represent pooled mean
values 5 SEM. ***p < 0.001, **p < 0.01
(two-sided Student’s t test).five TCGA individuals with cancer harbored germline
heterozygous SEC23B variants (c.40C>T [p.Arg14Trp],
c.649C>T [p.Arg217*], c.2101C>T [p.Arg701Cys],
c.74C>A [p.Pro25His], and c.689þ1G>C) known tobe asso-
ciatedwithCDAII in the homozygous or compound-hetero-
zygous setting. Because we cannot ascertain anemia-related
clinical phenotypes unrelated to cancer in these individuals,
such variants warrant further investigation. Interestingly,
irrespective of SEC23B-mutation status, an agnostic search
in the Catalogue of SomaticMutations in Cancer (COSMIC)
showed that 625/828 (~75%) of apparently sporadic cancers
of different types include overexpression of SEC23B tran-
scripts (Z score values > 2) and that 84/828 (~10%) show
high-level amplifications (gain of copy number), suggesting
that at least in a subset of cancers, SEC23B could indeed be
playing a previously unappreciated role in carcinogenesis
at large.
Given the role of SEC23B, we speculate that because of
the high demand for protein synthesis and traffickingThe Americanand, hence, increased sensitivity to perturbations in ER
function, germline SEC23B variants associate with cancers
in so-called professional secretory tissues (in this study,
thyroid, breast, and endometrium). Our functional data
also suggest that p.Val594Gly is a change-of-function
substitution that favors tumorigenesis even, or especially,
under stressful micro-environmental conditions. Cells
respond to ER stress by activating the unfolded protein
response (UPR), a signaling network that allows the recov-
ery of ER function by upregulating adaptive factors, such as
chaperone proteins and transcription factors, that regulate
protein synthesis, growth arrest, and ER biogenesis among
various pro-survival responses.59 Cell fate is largely deter-
mined by the intensity and duration of the stress stimuli,
and failure to adapt to ER stress ultimately leads to the acti-
vation of apoptotic pathways. Increasing evidence, how-
ever, suggests that cancer cells hijack or are addicted to
ER-stress-induced responses as a survival mechanism and
thus often confer resistance to anti-cancer therapies.60–65Journal of Human Genetics 97, 661–676, November 5, 2015 671
Figure 6. SEC23B Germline Heterozy-
gous Variants Cause Predisposition to He-
reditary and Apparently Sporadic Cancers
Abbreviations are as follows: CS, Cow-
den syndrome; TG, thapsigargin; TM,
tunicamycin.Mouse models completely deficient of SEC23B die
shortly after birth.36 Interestingly, these mice do not
have anemia but rather suffer from UPR-induced degener-
ation of professional secretory tissues that seem to highly
depend on SEC23B for efficient cargo transport and secre-
tion. More recently, it was reported thatmice with hemato-
poietic compartment localized deficiency of SEC23B also
show no red blood cell phenotypes.66 The difference in
phenotypes observed between humans and mice was
attributed to the existence of hypomorphic mutations in
humans and a potential species-specific overlap of func-
tion with the SEC23A paralog. Interestingly, Korpal and
colleagues agnostically identified that direct targeting of
SEC23A by miR200s promotes metastatic lung coloniza-
tion in mice by inhibiting the secretion of metastasis-
suppressive proteins and promoting the mesenchymal-
to-epithelial transition (MET).67 The appearance of large
epithelial colonies in our mutant Nthy-SEC23B-V594G
cells after ER stress is suggestive of a phenotype favoring
cell colonization. Whether this is conducive to primary
tumor formation or metastatic cell seeding has yet to
be determined. Moreover, increased MMP-2 and MMP-9
activity from the cell supernatant hints at the possi-
bility that protein-trafficking alterations modulate the
cell-derived secretome similarly to the newly discovered
SEC23A role in trafficking metastasis-regulating pro-
teins.67 Furthermore, the different migration patterns be-
tween Nthy cells and HEK293T cells transfected with our
mutant SEC23Bmight lend a clue. Althoughwe could attri-
bute differences to varying cellular contexts, HEK293Tcells
are immortalized with SV40 large T antigen, whereas Nthy
cells are immortalized with SV40, where the origin of repli-
cation is absent. One way or the other, we speculate that
the suspected heterozygous change-of-function SEC23B
mutations in a cancer context could override the existence
of wild-type SEC23A and SEC23B, at least in thyroid,
breast, and endometrial cancers, potentially through ER
stress and UPR ‘‘addiction.’’
However, the precise mechanism leading to neoplastic
transformation warrants further investigation. There is672 The American Journal of Human Genetics 97, 661–676, November 5, 2015indeed increasing evidence that
monoallelic and biallelic mutations
in a single gene can lead to completely
different phenotypes.5,68,69 Relatedly,
there are currently no reports of can-
cer predisposition in the obligate het-
erozygous parents of individuals with
CDAII. One possibility is that the car-
ried loss-of-function CDAII-associatedmutations result in a less severe hypomorphic phenotype
even in the heterozygous state, whereas we speculate that
cancer-promoting heterozygous variants do not affect pro-
tein stability and result in change-of-function effects. The
other possibility is that parents of CDAII individuals, espe-
cially if the latter are pediatric, might not be followed up
long enough for the existence of cancer to be ascertained.
This is confounded by the fact that CDAII is a rare disorder
with a global series of only 205 affected individuals (172
unrelated),52 and so it is plausible that the existence of
common cancers in these families might go unnoticed.
This phenomenon is paralleled by the discovery of germ-
line heterozygous mutations in FH (MIM: 136850), encod-
ing fumarate hydratase, in hereditary leiomyomatosis and
renal cell carcinoma (HLRCC [MIM: 150800]).69 Homozy-
gous or compound-heterozygous FH mutations cause
fumarase deficiency (FMRD [MIM: 606812]), a lethal neu-
ropathy, cardiopathy, and/or hepatopathy in infancy or
early childhood.68,70 The heterozygous parents of the indi-
viduals with these rare diseases are not documented to
have had cancer. Similarly, heterozygous SDHA, SDHB,
SDHC, and SDHDmutations were described to cause endo-
crine neoplasias71–73 only 13 years ago, whereas germline
homozygous or compound-heterozygous mutations in
SDHA, SDHB, SDHC, and SDHD (any one of four subunits
of succinate dehydrogenase or mitochondrial complex II)
have long been known to cause Leigh syndrome, a lethal
neuropathy that manifests shortly after birth.74,75 Yet,
none of the parents of individuals with Leigh syndrome
have been reported in the literature to have had compo-
nent cancers. Quite similar to Sec23b mouse models, the
existingmurinemodels of Sdhb, Sdhd, and Fh do notmimic
the human neoplasia conditions and indeed have little to
no phenotype (reviewed by Lepoutre-Lussey et al.76). It is
tempting to speculate on a ‘‘common’’ mechanism that
might explain the disparate phenotypes, namely cancer
and non-neoplastic yet extremely serious phenotypes,
between heterozygous and homozygous or compound-
heterozygous germline mutations in seemingly disparate
genes (SEC23B, SDHA, SDHB, SDHC, SDHD, and FH) and
the lack of the neoplastic phenotype in any of these hetero-
zygous mouse models.
We can only speculate that tissue-specific gene-dosage
thresholds and mutation-specific effects on encoded pro-
tein function might account for such differences. Notably,
our observations in the context of heterozygous SEC23B
mutations offer an important glimpse into how heritable
gene mutations interact with the environment (e.g., an
exposure leading to ER stress) to result in a particular dis-
ease phenotype (here, cancer)—and hence, genetic predis-
position to cancer. Indeed, vesicular trafficking is a major
contributor to carcinogenesis in that it modulates the traf-
ficking of key proteins involved in cell polarity, motility,
invasion, and cell-cell and cell-matrix interactions.77 Our
finding that heterozygous SEC23B germline variants exist
in CS and CSL individuals and in individuals with appar-
ently sporadic CS-component cancer is supported by
our in vitro data to indicate a role for SEC23B in cancer
predisposition when germline ‘‘change-of-function’’ vari-
ants constitutionally exist in the heterozygous context
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